Roche Holding AG Participation (ROGN)

8,464.050
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    8,464.050 - 8,464.050
  • Type:Equity
  • Market:Mexico
  • ISIN:CH0012032048

ROGN Overview

Prev. Close
8,455
Day's Range
8,464.05-8,464.05
Revenue
-
Open
8,464.05
52 wk Range
6,616-8,467.92
EPS
-
Volume
0
Market Cap
7.31T
Dividend (Yield)
9.10
(2.99%)
Average Volume (3m)
826
P/E Ratio
-
Beta
-
1-Year Change
24.21%
Shares Outstanding
800,951,903
Next Earnings Date
-
What is your sentiment on Roche Holding AG Participation?
or
Market is currently closed. Voting is open during market hours.

Roche Holding AG Participation Company Profile

Employees
101465

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women’s health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. The company has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. It also has a clinical collaboration with Carrick Therapeutics, Ltd. to evaluate a novel combination of Carrick’s samuraciclib and its giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer; a collaboration with Zur Rose Group AG to empower people with diabetes and their caregivers in their daily therapy management; and a research collaboration and license agreement with Venatorx Pharmaceuticals, Inc. to discover, characterize, and develop new small molecule inhibitors of the Penicillin Binding Proteins in Gram-negative bacteria focused on agents active against carbapenem-resistant Enterobacterales. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.